IN-VITRO EVALUATION OF THE EFFICACY AND BIOCOMPATIBILITY OF NEW, SYNTHETIC ABO IMMUNOABSORBENTS
IN-VITRO EVALUATION OF THE EFFICACY AND BIOCOMPATIBILITY OF NEW, SYNTHETIC ABO IMMUNOABSORBENTS
复制标题
DOI：
10.1097/00007890-199509000-00004
复制
发表时间：
1995-09-15
期刊：
影响因子：
6.2
通讯作者：
NYDEGGER, UE
中科院分区：
文献类型：
--
作者：
RIEBEN, R;KORCHAGINA, EY;NYDEGGER, UE
合成ABO免疫吸附剂（称为Synsorbs（R））已使用数年，以在ABO不相容器官或骨髓移植前特异性消除患者循环中的ABO抗体。由于Synsorbs不再可用，我们开发了新的ABO免疫吸附剂。这些物质分别称为生物吸附剂A和B，由通过聚丙烯酰胺共价偶联到大孔玻璃珠的合成A或B三聚体组成。与成人患者的免疫吸收程序相比，O型血血浆通过填充有环氧乙烷灭菌的生物吸附剂的柱，血凝在吸收后减少4个滴度步骤，并且抗A和/或抗B IgM/G/A，如通过ABO ELISA测量的，下降了85%或更多，而没有发生免疫球蛋白的非特异性吸收。未观察到补体的显著变化（经典途径的C3、C4和总溶血补体）或凝血参数（纤维蛋白原、凝血酶原时间、活化部分凝血活酶时间），如通过免疫印迹监测的，因子XII和高分子量激肽原均未被裂解。此外，单核细胞吞噬抑制试验提供了在吸收过程中没有发生IgG的显著聚集的证据。我们得出结论，生物吸附剂A和B是有效的，具体的，与人血浆的生物相容性。
Synthetic ABO immunoabsorbents (known as Synsorbs(R)) were in use for several years to specifically eliminate ABO antibodies from the patient's circulation before ABO-incompatible organ or bone marrow transplantation. Because Synsorbs are no longer available, we have developed new ABO immunoabsorbents,These substances, termed BioSorbents A and B, respectively, consist of synthetic A or B trisaccharides covalently coupled to macroporous glass beads via polyacrylamide, Here we report the evaluation of BioSorbents in regard to efficacy, specificity, and biocompatibility, Using a closed-circuit in vitro system, representing a 1:10-1:20 scale as compared with the immunoabsorption procedure with an adult patient, blood group O plasma was run through columns filled with ethylene oxide-sterilized BioSorbent, Hemagglutination was reduced by 4 titer steps after absorption, and anti-A and/or anti-B IgM/G/A, as measured by ABO ELISA, dropped by 85% or more, while no nonspecific absorption of immunoglobulins occurred. No significant changes could be observed for complement (C3, C4, and total hemolytic complement of the classical pathway) or for coagulation parameters (fibrinogen, prothrombin time, activated partial thromboplastin time), As monitored by immunoblotting, neither factor XII nor high molecular weight kininogen was cleaved, In addition, a monocyte phagocytosis inhibition test provided evidence that no significant aggregation of IgG had occurred during absorption. We conclude that BioSorbents A and B are efficient, specific, and biocompatible with human plasma.